Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBIT (2021 - 2025)

Historic EBIT for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to -$7.2 million.

  • Immunocore Holdings' EBIT rose 1565.51% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 3371.53%. This contributed to the annual value of -$70.5 million for FY2024, which is 1812.6% down from last year.
  • As of Q3 2025, Immunocore Holdings' EBIT stood at -$7.2 million, which was up 1565.51% from -$14.9 million recorded in Q2 2025.
  • Immunocore Holdings' EBIT's 5-year high stood at -$3.6 million during Q1 2025, with a 5-year trough of -$51.1 million in Q4 2021.
  • For the 5-year period, Immunocore Holdings' EBIT averaged around -$20.8 million, with its median value being -$15.4 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 8025.31% in 2024, then skyrocketed by 8634.96% in 2025.
  • Immunocore Holdings' EBIT (Quarter) stood at -$51.1 million in 2021, then surged by 36.43% to -$32.5 million in 2022, then skyrocketed by 47.48% to -$17.1 million in 2023, then dropped by 14.07% to -$19.5 million in 2024, then surged by 63.13% to -$7.2 million in 2025.
  • Its last three reported values are -$7.2 million in Q3 2025, -$14.9 million for Q2 2025, and -$3.6 million during Q1 2025.